Friday 6 November 2026 Export LNTH’s income statement to Excel — free account

Lantheus Holdings, Inc.

LNTH Healthcare Drug Manufacturers Specialty & Generic

Lantheus Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.5 billion, up 0.50% from fiscal 2024.

Revenue: +1.54%
EPS: −17.1%
Free cash flow: +7.71%
Total debt: +0.52%

Quarter to September 2026, against a year earlier

Revenue growth 5 yrs

100.76 0.38 −0.38%

Follow LNTH

Alert me

Market cap: $6.6B
P/E: 24.3×
Fwd P/E: 21.3×
Dividend yield: —
F-score: 5/9
Altman Z: 4.25
Beneish M: −2.23
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Lantheus Holdings, Inc. (LNTH) Price to free cash flow

Alert me on Price to free cash flow

As of 5 November 2026, Lantheus Holdings, Inc. (LNTH) trades at a price to free cash flow of 16.9×. Over the past ten years it has ranged from 0.0× (December 2015) to 299× (March 2021); the current reading is higher than 63% of that period. That is in line with the Drug Manufacturers Specialty & Generic industry median of 16.3× and below the Healthcare sector median of 21.1×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/LNTH/price-to-free-cash-flow" width="100%" height="360" style="border:0" loading="lazy" title="Lantheus Holdings, Inc. price to free cash flow, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/LNTH/metrics/price-to-free-cash-flow">Lantheus Holdings, Inc. (LNTH) price to free cash flow — stockrow.com</a></p>

Period	Price to free cash flow	Change
FY2025	12.7×	(1.05%)
FY2024	12.8×	6.11%
FY2023	12.1×	(7.66%)
FY2022	13.1×	(61.35%)
FY2021	33.8×	(81.82%)
FY2020	186×	1,258.06%
FY2019	13.7×	(3.62%)
FY2018	14.2×	(30.09%)
FY2017	20.3×	279.23%
FY2016	5.4×	(44.06%)

Period	Price to free cash flow	Change
Sep 2026	16.7×	(9.33%)
Jun 2026	18.4×	43.20%
Mar 2026	12.9×	1.30%
Dec 2025	12.7×	55.91%
43 more quarters	Free account

Against its own ten years

Low 0.0× High 299×

Ten-year median 15.1×

Current reading's percentile 63

Company	Price to free cash flow
AMRX AMNEAL PHARMACEUTICALS, INC. compare	n/m
AMLX Amylyx Pharmaceuticals, Inc. compare	n/m
LNTH Lantheus Holdings, Inc.	16.9×
LQDA Liquidia Corporation compare	26.4×
ALKS Alkermes plc compare	32.8×
KNSA Kiniksa Pharmaceuticals International, plc compare	35.1×
HIMS Hims & Hers Health, Inc. compare	67.3×
SUPN Indivior Pharmaceuticals Inc. compare	115×
RDY Dr. Reddy's Laboratories Ltd compare	126×
Drug Manufacturers Specialty & Generic industry median	16.3×
Healthcare sector median	21.1×
Market median	14.1×

What Price to free cash flow is

Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.

Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))

The full definition of Price to free cash flow →

Lantheus Holdings, Inc. (LNTH) Price to free cash flow

Price to free cash flow, daily

Annual newest first

Quarterly newest first

Against its own ten years

Price to free cash flow against peers

What Price to free cash flow is

More on LNTH

Price to free cash flow, daily

Annual newest first

Quarterly newest first

Against its own ten years

Price to free cash flow against peers

What Price to free cash flow is

More on LNTH

Stockrow Weekly